NTLA - Intellia Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
NTLA price evolution
NTLA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $226.75 | $168.03 | $171.81 | $294.15 |
| Short term investments | $685.48 | $686.76 | $736.27 | $639.39 |
| Net receivables | $36.46 | $6.49 | $5.06 | $4.91 |
| Inventory | ||||
| Total current assets | $998.33 | $893.49 | $939.62 | $963.67 |
| Long term investments | $154.51 | $197.28 | $226.88 | $294.35 |
| Property, plant & equipment | $148.13 | $152.57 | $156.74 | $159.87 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $302.65 | $349.86 | $383.63 | $454.22 |
| Total investments | $839.99 | $884.04 | $963.15 | $933.74 |
| Total assets | $1300.98 | $1243.35 | $1323.24 | $1417.89 |
| Current liabilities | ||||
| Accounts payable | $7.45 | $3.55 | $11.63 | $6.89 |
| Deferred revenue | $60.99 | $26.07 | $34.85 | $49.2 |
| Short long term debt | $18.6 | $17.07 | $16.75 | $16.33 |
| Total current liabilities | $115.21 | $91.95 | $99.85 | $103.38 |
| Long term debt | $96.75 | $101.26 | $105.58 | $109.8 |
| Total noncurrent liabilities | $135.6 | $113.98 | $118.5 | $123.66 |
| Total debt | $115.35 | $118.34 | $122.33 | $126.13 |
| Total liabilities | $250.81 | $205.94 | $218.35 | $227.05 |
| Shareholders' equity | ||||
| Retained earnings | -$1658.38 | -$1526.22 | -$1403.99 | -$1280.31 |
| Other shareholder equity | -$2.26 | -$3.57 | -$3.87 | -$2.68 |
| Total shareholder equity | $1050.17 | $1037.41 | $1104.89 | $1190.84 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $226.75 | $523.51 | $123.41 | $160.02 |
| Short term investments | $685.48 | $669.12 | $625.28 | $437.35 |
| Net receivables | $36.46 | $3.77 | $2.03 | $2.13 |
| Inventory | ||||
| Total current assets | $998.33 | $1216.8 | $769.3 | $616.52 |
| Long term investments | $154.51 | $142.32 | $425.05 | |
| Property, plant & equipment | $148.13 | $161 | $100.11 | $55.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $302.65 | $303.32 | $525.16 | $59.8 |
| Total investments | $839.99 | $811.44 | $1050.33 | $437.35 |
| Total assets | $1300.98 | $1520.11 | $1294.46 | $676.32 |
| Current liabilities | ||||
| Accounts payable | $7.45 | $5.15 | $9.65 | $10.46 |
| Deferred revenue | $60.99 | $63.77 | $127.23 | $73.93 |
| Short long term debt | $18.6 | $16.68 | $9.11 | $5.7 |
| Total current liabilities | $115.21 | $126.55 | $125.83 | $64.25 |
| Long term debt | $96.75 | $114.02 | $64.91 | $33.61 |
| Total noncurrent liabilities | $135.6 | $157.98 | $128.39 | $85 |
| Total debt | $115.35 | $130.7 | $74.02 | $39.3 |
| Total liabilities | $250.81 | $284.53 | $254.22 | $149.25 |
| Shareholders' equity | ||||
| Retained earnings | -$1658.38 | -$1177.19 | -$703 | -$435.11 |
| Other shareholder equity | -$2.26 | -$7.46 | -$2.63 | $0 |
| Total shareholder equity | $1050.17 | $1235.58 | $1040.24 | $527.07 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | -$1.92 | $11.99 | $13.59 | $12.61 |
| Cost of revenue | ||||
| Gross Profit | -$1.92 | $11.99 | $13.59 | $12.61 |
| Operating activities | ||||
| Research & development | $108.98 | $113.7 | $115.28 | $97.12 |
| Selling, general & administrative | $28.99 | $29.4 | $30.65 | $27.45 |
| Total operating expenses | $137.97 | $143.1 | $145.93 | $124.56 |
| Operating income | -$139.89 | -$131.11 | -$132.33 | -$111.96 |
| Income from continuing operations | ||||
| EBIT | -$132.16 | -$122.22 | -$123.68 | -$103.13 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$132.16 | -$122.22 | -$123.68 | -$103.13 |
| Income (for common shares) | -$132.16 | -$122.22 | -$123.68 | -$103.13 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.27 | $52.12 | $33.05 | $57.99 |
| Cost of revenue | ||||
| Gross Profit | $36.27 | $52.12 | $33.05 | $57.99 |
| Operating activities | ||||
| Research & development | $435.07 | $419.98 | $229.81 | $150.41 |
| Selling, general & administrative | $116.5 | $90.31 | $71.1 | $44.17 |
| Total operating expenses | $551.57 | $510.29 | $300.9 | $194.58 |
| Operating income | -$515.29 | -$458.16 | -$267.85 | -$136.58 |
| Income from continuing operations | ||||
| EBIT | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| Income (for common shares) | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$132.16 | -$122.22 | -$123.68 | -$103.13 |
| Operating activities | ||||
| Depreciation | $2.47 | $2.29 | $2.17 | $2.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $35.04 | $35.35 | $36.4 | $27.25 |
| Total cash flows from operations | -$93.05 | -$101.38 | -$90.32 | -$109.33 |
| Investing activities | ||||
| Capital expenditures | -$1.52 | -$4.33 | -$4.3 | -$3.83 |
| Investments | $47.46 | $83.83 | -$30.24 | -$118.42 |
| Total cash flows from investing | $45.94 | $79.5 | -$34.54 | -$122.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $104.61 | $19.1 | $0.47 | $2.22 |
| Net borrowings | ||||
| Total cash flows from financing | $106.48 | $19.1 | $2.52 | $2.22 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $59.37 | -$2.78 | -$122.34 | -$229.35 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$481.19 | -$474.19 | -$267.89 | -$134.23 |
| Operating activities | ||||
| Depreciation | $8.98 | $7.57 | $6.89 | $6.31 |
| Business acquisitions & disposals | -$44.83 | -$3 | ||
| Stock-based compensation | $134.05 | $91.4 | $47.01 | $19.9 |
| Total cash flows from operations | -$394.09 | -$333.29 | -$225.03 | -$49.91 |
| Investing activities | ||||
| Capital expenditures | -$13.98 | -$13.41 | -$12.76 | -$3.58 |
| Investments | -$17.36 | $218.55 | -$535.02 | -$210.9 |
| Total cash flows from investing | -$31.35 | $160.31 | -$550.78 | -$214.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $126.39 | $580.31 | $734.66 | $370.22 |
| Net borrowings | ||||
| Total cash flows from financing | $130.32 | $582.96 | $736.69 | $371.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$295.11 | $409.98 | -$39.12 | $107.38 |
News
Fundamentals
| Market cap | $1.97B |
|---|---|
| Enterprise value | $1.86B |
| Shares outstanding | 93.00M |
| Revenue | $36.27M |
|---|---|
| EBITDA | -$472.22M |
| EBIT | -$481.19M |
| Net Income | -$481.19M |
| Revenue Q/Q | -114.12% |
| Revenue Y/Y | -30.40% |
| P/E ratio | -4.09 |
|---|---|
| EV/Sales | 51.20 |
| EV/EBITDA | -3.93 |
| EV/EBIT | -3.86 |
| P/S ratio | 54.27 |
| P/B ratio | 1.87 |
| Book/Share | 11.32 |
| Cash/Share | 2.44 |
| EPS | -$5.17 |
|---|---|
| ROA | -36.42% |
| ROE | -43.91% |
| Debt/Equity | 0.24 |
|---|---|
| Net debt/EBITDA | -0.05 |
| Current ratio | 8.67 |
| Quick ratio | 8.67 |